Loading news...
Exane Asset Management acquired a new stake in Apogee Therapeutics Inc. (NASDAQ: APGE) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 51,543 shares of the company's stock, valued at approximately $2,048,000. Apogee Therapeutics comprises 0.7% of Exane Asset Management's investment portfolio, making
Guru Stock PicksChuck Royce has made the following transactions:Reduce in FC by 46.42%Add in SMP by 3.45%New position in ANDGStock News Minnesota CEOs call for
Guru Stock PicksBaillie Gifford has made the following transactions:Reduce in PBR.A by 0.13%Sold out in INSPAdd in TME by 0.27%New position in MICCStock News In
Stock News TikTok sets up U.S. data-security JV: TikTok USDS Joint Venture LLC launched as a majority American-owned entity to safeguard U.S. user data, algorit
Apogee Therapeutics (APGE) leverages IL-13 pathway optimization to enable less frequent dosing, targeting a leadership shift in biologic treatment for inflammatory diseases. APGE's $913 million cash position provides operational runway into 2028, supporting pivotal Phase II/III trials without near-term dilution risk. Zumilokibart's extended half-life and clean safety profile position APGE to challenge Dupixent, with physician surveys indicating strong preference for reduced dosing frequency.
The chief medical officer at Apogee Therapeutics sold 18,700 shares of the biotech for about $1.46 million. This sale represented 8.09% of Dambkowski's direct holdings, reducing his direct stake, as reported, from 231,223 to 212,523 shares.
Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report) insider Carl Dambkowski sold 18,700 shares of the firm's stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $77.84, for a total transaction of $1,455,608.00. Following the completion of the sale, the insider owned 212,523 shares of the company's
10,900 shares directly sold for a total transaction value of $817,500 on Dec. 4, 2025. The transaction represented 3.87% of CMO Carl Dambkowski's direct holdings, reducing direct ownership from 282,008 to 271,108 shares.
Apogee Therapeutics (NASDAQ: APGE) presented interim Phase 1b data for its IL-13 antibody zumilokibart (APG777) in mild to moderate asthma, highlighting what the company described as a robust and durable reduction in fractional exhaled nitric oxide (FeNO) following a single dose. Executives positioned the readout as the first of four key clinical catalysts expected in 2026
Apogee Therapeutics, Inc. (APGE) Discusses Interim Phase Ib Results of Zumilokibart for Mild-to-Moderate Asthma and Pipeline Developments Transcript
Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of FeNO through 32 weeks for patients with available follow up - Results reinforce continued development in asthma testing every 3- or 6-month dosing
SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report interim results from its Phase 1b trial of APG777 in patients with mild-to-moderate asthma on Tuesday, January 6, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m.
Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report) has earned an average rating of "Moderate Buy" from the twelve analysts that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eight have issued a buy recommendation and two have given a
Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report) shares hit a new 52-week high during trading on Friday. The company traded as high as $80.00 and last traded at $80.00, with a volume of 9086 shares. The stock had previously closed at $77.35. Wall Street Analyst Weigh In A number of equities research analysts
Jazz Pharmaceuticals (NASDAQ: JAZZ - Get Free Report) and Apogee Therapeutics (NASDAQ: APGE - Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations. Valuation and Earnings This table compares Jazz
Apogee Therapeutics, Inc. (APGE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Here is how Apogee Therapeutics Inc. (APGE) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026, APEX 16-week Part B data in AD in Q2 2026, and APG279 Phase 1b head-to-head readout against DUPIXENT in AD in 2H 2026
Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and 6- month dosing
SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences. Guggenheim 2 nd Annual Healthcare Innovation Conference Date: Tuesday, November 11, 2025Fireside Chat Time: 1:30 p.m.